Trial Details

Not Recruiting
Basic Information
Clinical ID c5494
Identifier ACTRN12614000903684
Trial Title A Randomized, Single-blind, Single-dose, 3-arm, Parallel Group Study to Determine the Pharmacokinetic Similarity of ABP 710 and Infliximab (Remicade 'Registered Trademark') in Healthy Adult Subjects
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Infliximab is currently used to treat patients with adult and pediatric inflammatory conditions. These inflammatory conditions affects various body systems such as gastrointestinal (Crohn's disease).;Infliximab is currently used to treat patients with ad
Interventions Arm 1: ABP 710 5 mg/kg (100 mg vial)Arm 2: infliximab 5 mg/kg (FDA-licensed 100 mg vial)Arm 3: infliximab 5 mg/kg (EU-authorized; 100 mg vial)Subjects will be randomised to receive intravenous infusion of ABP 710 5 mg/kg (Treatment Arm 1),
Participant Information
Sponsor Amgen Inc, USA.
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type Interventional
Phase PHASE1
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL